ki:elements Detects Alzheimer’s Pathology via Automated Phone Call: Study Validates Speech Biomarker Across Five European Cohorts
New peer-reviewed research published by ki:elements and the PROSPECT-AD consortium demonstrates that the company’s Speech Biomarker for Cognition (SB-C) can reliably detect cognitive impairment and signal underlying Alzheimer’s disease (AD) pathology through an AI voice agent that calls participants at home. The study, involving 736 participants across five independent cohorts in Spain, the UK, Germany and Sweden, is one of the largest and most geographically diverse validations of a speech-based digital cognitive assessment to date.
The research confirms that the SB-C consistently separated cognitive unimpaired individuals from those with mild cognitive impairment (MCI) or early dementia. Notably, the tool demonstrated a significant ability to classify Alzheimer’s CSF biomarker status remotely. It identified amyloid-beta positivity with an AUC of up to 0.74 and phosphorylated tau 181 positivity with an AUC of up to 0.82.
A Scalable Pre-Screen for Clinical Trials
Recruiting for AD clinical trials is traditionally one of the costliest phases of drug development, often requiring invasive and expensive procedures like lumbar punctures or PET scans to confirm eligibility. The SB-C offers the biopharma industry a validated first-pass enrichment layer, identifying individuals most likely to meet biomarker-positive eligibility criteria before committing to expensive invasive procedures.
